Business Daily from THE HINDU group of publications
Saturday, Dec 06, 2008
ePaper | Mobile/PDA Version | Audio | Blogs
News
Features
Stocks
Cross Currency
Shipping
Archives
Google

Group Sites

 Corporate - Regulatory Bodies & Rulings
Aurobindo Pharma gets USFDA nod

Hyderabad, Dec. 5

Aurobindo Pharma Ltd has received tentative approval from the US Food and Drug Administration for Perindopril Erbumine tablets and Escitalopram Oxalate oral solution. The tablets and oral solution are indicated for the treatment of hypertension depressive disorders respectively. Perindopril erbumine tablets are generic equivalent of Solvay Pharmaceuticals’ Aceon while Oxalate oral solution is the generic equivalent of Forest Laboratories’ Lexapro, the company s aid in a release. —

Our Bureau

More Stories on : Regulatory Bodies & Rulings | Pharmaceuticals

Article E-Mail :: Comment :: Syndication :: Printer Friendly Page

Stories in this Section
Temporary shutdown at Bosch plant

Sandvik goes for 5-day week
BHEL bags order from Oman for gas turbines
Who’ll shell out the tax?
Tata Motors counsel’s arguments
Vodafone, Hutchison Tele transfer relates to assets in India, says HC
Indo Tech Transformers sells out to Prolec-Ge of Mexico
Indian Oil commissions first LPG pipeline
Coal India suggests minor relocation of Durgapur Aerotropolis project
Suprajit sets up export oriented unit in Bangalore
Aurobindo Pharma gets USFDA nod
NTPC-Nuclear Power Corpn venture to be in place by Jan
‘I’ve never seen such a positive environment for renewable energy’
ISO certification for hotel
US woes not to hit Indian vendors, says GM
Toyota’s Corolla Altis, Innova to cost more
EWDPL eyes cash-strapped cos to fuel growth




Smartbuy
The Hindu Group: Home | About Us | Copyright | Archives | Contacts | Subscription
Group Sites: The Hindu | The Hindu ePaper | Business Line | Business Line ePaper | Sportstar | Frontline | The Hindu eBooks | The Hindu Images | Home |

Copyright © 2008, The Hindu Business Line. Republication or redissemination of the contents of this screen are expressly prohibited without the written consent of The Hindu Business Line